UPC APP 11293/2025
EP2401365 · REENGINEERING MRNA PRIMARY STRUCTURE FOR ENHANCED PROTEIN PRODUCTION
- Case details
- Status—ActionPreliminary objectionCategoryPreliminary objection
- Parties
- Respondents
- BioNTech SEOperating co.
- BioNTech Manufacturing GmbHOperating co.
- BioNTech Manufacturing Marburg GmbHOperating co.
- BioNTech Innovative Manufacturing Services GmbHOperating co.
- BioNTech Europe GmbHOperating co.
- Pfizer Manufacturing Belgium NVOperating co.
- Pfizer SASOperating co.
- Pfizer ABOperating co.
- Pfizer Inc.Operating co.
Representatives- Christine Kanz-Hoyng Rokh Monegier
- Tobias J. Hessel-Clifford Chance Partnerschaft mbB
- Division
- Munich LD
- Judges
- Technology
- ChemistryBiotechnology
- Language
- —
- First decided
- Apr 17, 2025
| Median days to first decision | |
|---|---|
| All UPC | 124 |
| Munich LD | Locked |
| Judge András Kupecz | Locked |
At the UPC: Promosome LLC (15 cases)·BioNTech Group (21 cases)
This dispute contains 14 other proceedings
UPC CoA 146/2026·UPC CoA 147/2026·UPC CoA 148/2026·UPC CFI 2819/2026·UPC CFI 2821/2026 and 9 more
- 2025-04-17Preliminary objectionPublic
Summary: Munich Local Division order (judge-rapporteur Kupecz) deferring the preliminary objection by BioNTech and Pfizer defendants to be dealt with in the main infringement proceedings. Promosome LLC sued BioNTech/Pfizer for infringement of EP 2 401 365 (mRNA patent) via Comirnaty COVID-19 vaccines. Defendants raised a preliminary objection challenging UPC jurisdiction over acts committed before 1 June 2023. The court found the objection admissible but ordered it to be resolved in the main proceedings (R. 20.2 RoP). Jurisdiction over acts from 1 June 2023 onward was uncontested.
Show the legal issues (3)
- Preliminary objection on temporal jurisdiction (Art. 32/3 UPCA)
- UPC jurisdiction over pre-UPCA entry into force infringement acts
- mRNA vaccine technology / Comirnaty COVID-19 vaccine
- AA7716ACE1F678AB21A88B9BD0BB3072_en.pdf2025-04-17EN